1. A continuous casting method, comprising the following steps of:
guiding molten steel from an immersion nozzle into a mold;
guiding a slab formed in said mold to a plurality of guide roll pairs;
bulging said slab by providing an increased spacing between a select number of the guide roll pairs to produce a bulged slab with a liquid core;
completing the solidification of a liquid core in a thickness-wise center part of said bulged slab at the position where the bulged slab is reduced, and
reducing the thickness of said bulged slab to a predetermined thickness with a reduction roll pair comprising an upper reduction roll and a lower reduction roll, wherein the uppermost surface of said lower reduction roll is projected a distance higher than a lower pass line for the slab, wherein the projection distance of the uppermost surface of the lower reduction roll from the lower pass line for the slab is based on a bulging thickness of the slab and the projection distance is the same as or not more than a bulging thickness of the bulged slab,
wherein by reducing the bulged slab, a Mn segregation index CC0 in the thickness-wise center part satisfies the relation expressed by the following equation (a) over the width W which is expressed by the following equation (b):
0.7\u2266CC0\u22661.2 \u2003\u2003(a), and
W=W0\u22122\xd7d\u2003\u2003(b)
where C: the Mn content (mass %) at the center part in the thickness direction of the slab,
C0: the mean Mn content (mass %) in the slab,
W0: the width of the slab (mm), and
d: the thickness of the solidified shell (the distance between an area of the slab with a solid fraction of 0.8 and a surface layer on a narrow side at the position of thickness reduction) (mm).
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for treatment of cancer comprising administering to a subject in need thereof a therapeutically effective dose of glufosfamide in combination with carboplatin and etoposide.
2. The method of claim 1 further comprising administering rituximab.
3. The method of claim 1 wherein said cancer is a lymphoma.
4. The method of claim 3 wherein said cancer is a non-Hodgkin’s lymphoma.
5. The method of claim 3 wherein said cancer is a Hodgkin’s lymphoma
6. The method of claim 1 wherein said glufosfamide is administered in the absence of mesna.
7. The method of claim 1 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.
8. The method of claim 2 wherein said cancer is a lymphoma.
9. The method of claim 8 wherein said cancer is a non-Hodgkin’s lymphoma.
10. The method of claim 8 wherein said cancer is a Hodgkin’s lymphoma
11. The method of claim 2 wherein said glufosfamide is administered in the absence of mesna.
12. The method of claim 8 wherein said glufosfamide is administered in the absence of mesna.
13. The method of claim 2 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.
14. The method of claim 3 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.
15. The method of claim 4 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.
16. The method of claim 5 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.
17. The method of claim 6 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.
18. The method of claim 8 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.
19. The method of claim 9 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.
20. The method of claim 10 wherein glufosfamide is administered for one or more dosage cycles, each cycle comprising infusion in the range of:
a): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; about 1.5 to about 4.5 gm2; about 4.5 to about 8.0 gm2; about 4.5 to about 6.0 gm2; or about 4.5 to about 5.0 gm2 or over an infusion period of 1-6 hours once every three weeks;
b): about 1.5 to about 3.0 gm2 or about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours for three consecutive days (days 1, 2 and 3): every three weeks;
c): about 1.5 to about 2.0 gm2 over an infusion period of 1-6 hours once per week; or
d): about 1.5 to about 8.0 gm2; about 1.5 to about 6.0 gm2; or about 1.5 to about 4.5 gm2 over an infusion period of 1-6 hours once every four weeks.